Skip to main content
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. — Investor Relations & Filings

Ticker · DNLI ISIN · US24823R1059 LEI · 549300ZTQ2HO18L3Q830 US Manufacturing
Filings indexed 749 across all filing types
Latest filing 2022-08-23 Director's Dealing
Country US United States of America
Listing US DNLI

About Denali Therapeutics Inc.

https://www.denalitherapeutics.com

Denali Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases, lysosomal storage disorders, and other serious illnesses. The company's core scientific strategy centers on its proprietary Transport Vehicle™ (TV) platform, which is engineered to transport large therapeutic molecules, such as antibodies and enzymes, across the blood-brain barrier. This technology is designed to overcome a primary obstacle in treating diseases of the central nervous system. Denali's pipeline comprises a portfolio of investigational drug candidates that leverage this platform to target the underlying genetic and biological pathways of complex diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-08-23 English
FORM 4
Director's Dealing
2022-08-12 English
FORM 4
Director's Dealing
2022-08-12 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2022, by Denali Therapeutics Inc. It announces the issuance of a press release with financial results for the second quarter ended June 30, 2022. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as Exhibit 99.1. The length of the document is 3485 characters, which is relatively short and consistent with an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement of financial results, not the full earnings release or quarterly report itself. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results.
2022-08-08 English
FORM 4
Director's Dealing
2022-07-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.